Valuation: ARPIDA

Market Cap 17.52M 21.86M 18.73M 16.04M 30.1M 2.09B 30.5M 207M 80.74M 1.05B 82.1M 80.31M 3.48B P/E 2024
6.22x
P/E 2025 -8.95x
Enterprise Value 11.62M 14.5M 12.42M 10.64M 19.96M 1.39B 20.22M 137M 53.53M 697M 54.43M 53.25M 2.3B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
58.74%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Investor Relations Contact 59 -
Director TitleAgeSince
Director/Board Member - 27/03/2025
Chairman - 27/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
+1.09%+5.26%+4.44%+26.03% 51.22B
-1.07%+2.82%+474.18%+601.24% 45.38B
+1.47%+9.79%+40.15%+21.21% 42.15B
+1.44%+7.77%+19.27%+90.94% 41.97B
-0.93%-4.33%+17.87%+51.96% 31.95B
+1.32%+7.30%+36.93%+152.36% 17.1B
-0.60%+1.93% - - 16.73B
+0.03%+3.41%+7.12%+35.49% 14.76B
+1.28%+5.41%+91.01%+46.93% 13.91B
Average +0.45%+3.68%+86.37%+128.27% 30.58B
Weighted average by Cap. +0.48%+3.55%+103.78%+150.02%

Financials

2024 2025
Net sales - -
Net income 1.04M 1.3M 1.12M 955K 1.79M 125M 1.82M 12.33M 4.81M 62.59M 4.89M 4.78M 207M -653K -814K -698K -597K -1.12M -77.92M -1.14M -7.71M -3.01M -39.14M -3.06M -2.99M -129M
Net Debt -6.75M -8.43M -7.22M -6.18M -11.6M -806M -11.75M -79.79M -31.11M -405M -31.64M -30.95M -1.34B -5.91M -7.37M -6.31M -5.41M -10.15M -705M -10.28M -69.77M -27.21M -354M -27.67M -27.06M -1.17B
Logo ARPIDA
EvoNext Holdings Ltd, previously Evolva Holding Ltd, is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.
Employees
-